Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Clinical trial NCT06350110 · RECRUITING

Trial details

NCT number: NCT06350110
Sponsor: Essen Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus Lupus Nephritis Autoimmune Diseases Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Granulomatous Polyangiitis Microscopic Polyangiitis Systemic Sclerosis Idiopathic Inflammatory Myopathies Sjogren's Syndrome

Start date: 2024-07-10
Primary completion: 2025-12-10
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.